Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity

Featuring an interview with Dr Erica Mayer, including the following topics:

• Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)
• Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)
• Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)
• Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)
• Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)
• Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)
• Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)
• Investigator Survey Results on Adjuvant Oral SERDs (43:02)
• Discussion of Questions from the Community (45:00)

CME information and select publications